| 0.0013 -0.002 (-53.57%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0 |
1-year : | 0 |
| Resists | First : | 0 |
Second : | 0 |
| Pivot price | 0 |
|||
| Supports | First : | 0 |
Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0 |
| MA(100) : | 0.01 |
MA(250) : | 341 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.2 |
D(3) : | 14.4 |
| RSI | RSI(14): 21.3 |
|||
| 52-week | High : | 8542.79 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADTX ] has closed below the lower bollinger band by 17.1%. Bollinger Bands are 99.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 231 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
Thu, 15 Oct 2026
Aditxt and Copley Mutually Terminate Ignite Proteomics SPAC Business Combination - TradingView
Wed, 07 Oct 2026
Nasdaq says it met its rules to remove Aditxt (OTC: ADTX) common stock from listing. - Stock Titan
Wed, 23 Sep 2026
Nasdaq to delist Aditxt (ADTX) as shares shift to OTC trading - Stock Titan
Thu, 25 Jun 2026
Aditxt (ADTX) Stock Sinks 20% After-Hours: Here’s What’s Going On - Benzinga
Wed, 24 Jun 2026
Nasdaq panel moves to delist Aditxt (NASDAQ: ADTX) after rule breaches - Stock Titan
Mon, 22 Jun 2026
Investment firm Takeover Time 2026 LLC (ADTX) discloses 10.9% Aditxt stake - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | -19 (M) |
| Held by Insiders | -1.235e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 815 (K) |
| Shares Short P.Month | 997,980 (K) |
| EPS | 2850 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25 |
| Profit Margin | 0 % |
| Operating Margin | -35 % |
| Return on Assets (ttm) | 873.5 % |
| Return on Equity (ttm) | -50.8 % |
| Qtrly Rev. Growth | 14340 % |
| Gross Profit (p.s.) | -59.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -44721.9 |
| Qtrly Earnings Growth | -1.808e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0.46 |
| Forward Dividend | 0.4 |
| Dividend Yield | 35384.6% |
| Dividend Pay Date | 2000-06-09 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|